Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Gross Profit (2016 - 2025)

Collegium Pharmaceutical has reported Gross Profit over the past 10 years, most recently at $128.4 million for Q4 2025.

  • Quarterly results put Gross Profit at $128.4 million for Q4 2025, up 30.61% from a year ago — trailing twelve months through Dec 2025 was $463.3 million (up 22.77% YoY), and the annual figure for FY2025 was $463.3 million, up 22.77%.
  • Gross Profit for Q4 2025 was $128.4 million at Collegium Pharmaceutical, down from $129.2 million in the prior quarter.
  • Over the last five years, Gross Profit for COLL hit a ceiling of $129.2 million in Q3 2025 and a floor of -$1.3 million in Q4 2021.
  • Median Gross Profit over the past 5 years was $78.9 million (2023), compared with a mean of $76.3 million.
  • Biggest five-year swings in Gross Profit: plummeted 103.01% in 2021 and later surged 3835.11% in 2022.
  • Collegium Pharmaceutical's Gross Profit stood at -$1.3 million in 2021, then surged by 3835.11% to $49.8 million in 2022, then surged by 90.06% to $94.6 million in 2023, then grew by 3.87% to $98.3 million in 2024, then soared by 30.61% to $128.4 million in 2025.
  • The last three reported values for Gross Profit were $128.4 million (Q4 2025), $129.2 million (Q3 2025), and $108.4 million (Q2 2025) per Business Quant data.